Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet, indicated for the treatment of high blood pressure and high cholesterol.


Ranbaxy Pharmaceuticals, generic version of Caduet, Caduet authorized generic, Caduet, Pfizer, atorvastatin, amlodipine, high blood pressure, high cholesterol, hypertension, authorized generic, cholesterol-reducing medication, Venkat Krishnan, Lipitor


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Ranbaxy rolls out Caduet authorized generic

December 7th, 2011

PRINCETON, N.J. – Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet, indicated for the treatment of high blood pressure and high cholesterol.

Ranbaxy said Tuesday that the product is being introduced in the U.S. market under an agreement with Pfizer Inc.

Caduet is a fixed-dose combination of atorvastatin (for managing cholesterol levels) and amlodipine besylate (for controlling hypertension). For the year ended in September, Caduet had total U.S. sales of $339 million, according to IMS Health data reported by Ranbaxy.

Ranbaxy said it's making available the full range of the generic version of Caduet.

"The introduction of atorvastatin-amlodipine besylate tablets is a significant and important addition to our portfolio of cardiovascular products in the U.S.," stated Venkat Krishnan, senior vice president and regional director for the Americas at Ranbaxy. "The launch further complements our resolve to bring high-quality, affordable generic medicines as early as possible to the U.S. health care system, benefitting a wider cross-section of people."

Last week, Ranbaxy announced the launch of atorvastatin calcium tablets, a generic version of the cholesterol-reducing medication Lipitor, in the U.S. market after being cleared by the Food and Drug Administration to manufacture and market the drug.

Advertisement